Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.

Boikos SA, Hammers HJ.

J Clin Oncol. 2012 Oct 10;30(29):e299. doi: 10.1200/JCO.2012.41.7923. Epub 2012 Sep 4. No abstract available.

PMID:
22949145
2.

Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.

Adhikaree J, Newby Y, Sundar S.

BMJ Case Rep. 2014 Jan 30;2014. pii: bcr2013202861. doi: 10.1136/bcr-2013-202861.

3.

Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.

Massaro AM.

Cancer Pract. 2002 Jul-Aug;10(4):219-21. No abstract available.

PMID:
12100107
4.

Denosumab and bone metastases. No better than a bisphosphonate.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):204-6. Review.

PMID:
23016249
5.

[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].

Arima S, Shiroki R, Mori S, Maruyama T, Sasaki H, Kusaka M, Miyakawa S, Hayakawa K, Hoshinaga K.

Nihon Hinyokika Gakkai Zasshi. 2008 Jul;99(5):660-5. Japanese.

6.

Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.

Diel IJ, Bergner R.

Oncologist. 2005 Jan;10(1):82-3; author reply 84-7. No abstract available.

7.

Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.

Freeman A, El-Amm J, Aragon-Ching JB.

Clin Genitourin Cancer. 2013 Dec;11(4):e24-6. doi: 10.1016/j.clgc.2013.06.002. Epub 2013 Sep 2. No abstract available.

PMID:
24007982
8.

Dose of bisphosphonate for hypercalcaemia of malignancy.

Morton AR, Friefeld J, Halperin F.

Lancet. 1990 Jun 16;335(8703):1469-70. No abstract available.

PMID:
1972245
9.

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

Vincenzi B, Santini D, La Cesa A, Tonini G.

Cancer. 2004 May 1;100(9):1987-8; author reply 1988. No abstract available.

10.

[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].

Kise H, Kobayashi K, Arima K, Yanagawa M, Tochigi H, Kawamura J, Hioki T, Sugiura Y.

Hinyokika Kiyo. 1996 Nov;42(11):879-81. Japanese.

11.

Hypercalcemia in patients with metastatic renal cell carcinoma: effect of nephrectomy and metabolic evaluation.

Walther MM, Patel B, Choyke PL, Lubensky IA, Vocke CD, Harris C, Venzon D, Burtis WJ, Linehan WM.

J Urol. 1997 Sep;158(3 Pt 1):733-9.

PMID:
9258070
12.

Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Tsuda M, Ishiguro H, Yano I, Toi M.

J Natl Cancer Inst. 2014 Jun 6;106(7). pii: dju137. doi: 10.1093/jnci/dju137. Print 2014 Jul. No abstract available.

PMID:
24906398
13.

Hypercalcemia upon recurrence of renal cell carcinoma producing parathyroid hormone-related protein.

Ueno M, Tokonabe S, Kuroda I, Tsukamoto T, Deguchi N.

Scand J Urol Nephrol. 2003;37(3):265-8.

PMID:
12775288
14.

RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Adhikaree J, Newby Y, Sundar S.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju509. doi: 10.1093/jnci/dju509. Print 2015 Mar. No abstract available.

PMID:
25663690
15.

[Refractory hypercalcemia in patient with lung cancer].

Grzywacz A, Dziuk M, Niemczyk S.

Pol Merkur Lekarski. 2014 Apr;36(214):261-4. Polish.

PMID:
24868900
16.

Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.

Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.

Clin Cancer Res. 2005 Jun 1;11(11):4198-203.

17.

Hand metastasis in renal cell carcinoma.

Fusetti C, Kurzen P, Bonaccio M, B├╝chler U, Nagy L.

Urology. 2003 Jul;62(1):141. No abstract available.

PMID:
12837444
18.

Overdosage of pamidronate in a patient with renal cell carcinoma.

Akbulut H, Icli F.

Med Oncol. 2000 Nov;17(4):340-1. No abstract available.

PMID:
11114716
19.

Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?

Bech A, Essink G, de Boer H.

Neth J Med. 2012 Jun;70(5):250-1. No abstract available.

20.

The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.

Fountas A, Andrikoula M, Giotaki Z, Limniati C, Tsakiridou E, Tigas S, Tsatsoulis A.

Endocr Pract. 2015 May;21(5):468-73. doi: 10.4158/EP14410.OR. Epub 2015 Feb 9.

PMID:
25667369

Supplemental Content

Support Center